Wake Forest University Health Sciences

1. Moderna TX, Inc. $6,840,116 1,912 payments
2. Novartis Pharmaceuticals Corporation $4,217,361 59 payments
3. Amgen Inc. $3,693,044 109 payments
4. Renalytix AI, Inc. $2,574,602 7 payments
5. Regeneron Pharmaceuticals, Inc. $2,548,926 891 payments
6. Aadi Bioscience, Inc. $1,609,289 266 payments
7. Eli Lilly and Company $1,340,084 57 payments
8. Abbott Laboratories $1,311,487 205 payments
9. Biogen, Inc. $1,249,690 25 payments
10. Merck Sharp & Dohme Corporation $1,194,558 19 payments

1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $4,725,088 212 payments
2. A Prospective Decision Impact Trial of Kidneyintelxtm in Patients With Type 2 Diabetes and Existing Chronic Kidney Disease $2,430,592 5 payments
3. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $1,627,478 12 payments
4. Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer $1,564,589 242 payments
5. A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2Nd Line Chronic Phase - Chronic Myelogenous Leukemia $1,322,336 5 payments
6. An Open-Label Study to Assess the Anti-Tumor Activity and Safety of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, in Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma $893,992 74 payments
7. A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma $654,131 39 payments
8. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $627,902 1,211 payments
9. Phase 1B Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma $611,156 274 payments
10. A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia $590,550 25 payments

1. Professional salary support $147,629 17 payments
2. Patient care $125,895 60 payments
3. Overhead $60,000 3 payments
4. Other $6,685 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.